of RNA medicines.

Orbital Therapeutics is on a mission to enhance global health by unleashing the full potential of RNA medicines to treat human disease in ways that were not previously possible.

Our comprehensive platform aims to align with and treat disease with programmable RNA therapeutics. We have built a collection of best-in-class tools that integrate established and emerging technologies, designed to engineer novel RNA medicines with advanced programmability, potential for improved durability, and expanded delivery to different tissues.

our platform

We are pursuing an expansive therapeutic portfolio of RNA medicines spanning many diseases, initially focused on immunomodulation for autoimmune disease and oncology, next-generation vaccines, and protein therapeutics.

our pipeline

We are a values-driven organization with a commitment to innovation and inclusivity, built with high caliber science, state-of-the-art technologies, and a world-class team.

our values

Founded by experts in the fields of genetic medicine and RNA development and delivery, Orbital has a deeply skilled organization assembled to harness the ingenuity of a diverse team of scientists, drug developers, and business leaders.

Management Team

Giuseppe Ciaramella, Ph.D.
Chief Executive Officer, Director & Co-Founder
Gilles Besin, Ph.D.
Chief Scientific Officer
Jonathan Piazza
Chief Financial Officer
Jeff Munsie
Chief Legal Officer
Susan O’Connor
Chief Human Resources Officer

Board of Directors

John Maraganore, Ph.D.
Chairman & Co-Founder
Kristina Burow
Director & Co-Founder
Carol Suh
Director & Co-Founder
Vineeta Agarwala, M.D., Ph.D.
John Evans
Giuseppe Ciaramella, Ph.D.
Chief Executive Officer, Director & Co-Founder

Scientific Co-Founders



This links to an external website.